Upstream Bio, Inc. (UPB)
- Previous Close
8.21 - Open
8.15 - Bid 6.54 x 200
- Ask 8.64 x 100
- Day's Range
8.06 - 9.16 - 52 Week Range
5.14 - 29.46 - Volume
252,953 - Avg. Volume
279,339 - Market Cap (intraday)
461.55M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-5.58 - Earnings Date May 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
49.67
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
upstreambio.comRecent News: UPB
View MorePerformance Overview: UPB
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UPB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UPB
View MoreValuation Measures
Market Cap
461.55M
Enterprise Value
-7.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
49.53
Price/Book (mrq)
0.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.91%
Return on Equity (ttm)
-23.29%
Revenue (ttm)
2.3M
Net Income Avi to Common (ttm)
-89.66M
Diluted EPS (ttm)
-5.58
Balance Sheet and Cash Flow
Total Cash (mrq)
431.38M
Total Debt/Equity (mrq)
0.38%
Levered Free Cash Flow (ttm)
-70.18M